<DOC>
	<DOCNO>NCT00005965</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness bryostatin-1 plus cisplatin treating patient recurrent advanced cancer cervix .</brief_summary>
	<brief_title>Bryostatin-1 Plus Cisplatin Treating Patients With Recurrent Advanced Cancer Cervix</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety efficacy bryostatin-1 plus cisplatin patient recurrent advance carcinoma cervix . II . Determine response rate , progression free interval , duration survival patient treat regimen . OUTLINE : This multicenter study . Patients receive bryostatin-1 IV 1 hour cisplatin IV 1 hour day 1 . Treatment continue every 21 day absence disease progression unacceptable toxicity . Patients follow death . PROJECTED ACCRUAL : A total 37 patient accrue study 2-3 year .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Adenosquamous</mesh_term>
	<mesh_term>Bryostatin 1</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent advance carcinoma cervix amenable surgery radiotherapy Squamous cell OR Adenocarcinoma OR Adenosquamous carcinoma Measurable disease Brain metastasis treat surgery radiotherapy allow residual symptom medication ( e.g. , anticonvulsant , corticosteroid ) PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin great 9 g/dL Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) AST/ALT le 2.5 time ULN Renal : Creatinine great 1.5 mg/dL Cardiovascular : No severe cardiac dysfunction arrhythmia Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent unstable medical illness , infection , significant medical problem No clinically apparent neuropathy , include hear loss No psychological , familial , sociological , geographical condition may preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Prior neoadjuvant chemosensitization therapy allow At least 3 week since prior chemotherapy ( 6 week since prior mitomycin nitrosoureas ) recover Prior cisplatin therapy allow No prior chemotherapy advance disease Endocrine therapy : No concurrent corticosteroid Radiotherapy : At least 2 week since prior radiotherapy recover Surgery : Prior surgery allow Other : No concurrent anticonvulsants No concurrent antiarrhythmic medication</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2004</verification_date>
	<keyword>stage III cervical cancer</keyword>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>stage IVB cervical cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
	<keyword>cervical squamous cell carcinoma</keyword>
	<keyword>cervical adenocarcinoma</keyword>
	<keyword>cervical adenosquamous cell carcinoma</keyword>
</DOC>